Anakinra Market Report 2026

Anakinra Market Overview

• Anakinra market size has reached to $5.46 billion in 2025 • Expected to grow to $9.61 billion in 2030 at a compound annual growth rate (CAGR) of 11.9% • Growth Driver: Rising Incidence Of Autoimmune Disorders Driving Market Growth Due To Increased Need For Targeted Immunomodulatory Therapies • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Anakinra Market?

Anakinra refers to a biopharmaceutical medication that acts as a recombinant version of the human interleukin-1 receptor antagonist. It is generally used to treat moderate-to-severe rheumatoid arthritis in individuals who have not reacted well to other disease-modifying antirheumatic medications. The main types of indications for anakinra are rheumatoid arthritis, cryopyrin-associated periodic syndromes, familial cold autoinflammatory syndrome, systemic juvenile idiopathic arthritis, adult-onset Still's disease, neonatal-onset multisystem inflammatory disease, and others. Rheumatoid arthritis refers to a chronic autoimmune disease in which the immune system erroneously attacks the body's own joint tissues, particularly the synovium. It is distributed through hospital pharmacies, retail pharmacies, online pharmacies, and wholesale pharmacies, catering to various end users, including hospitals, clinics, and home care settings.

What Is The Anakinra Market Growth Forecast?

The anakinra market size is expected to see rapid growth in the next few years. It will grow to $9.61 billion in 2030 at a compound annual growth rate (CAGR) of 11.9%. The growth in the forecast period can be attributed to growth in biologic therapies, rising rare disease diagnosis, expansion of homecare settings, increasing immunology trials, growing healthcare access. Major trends in the forecast period include rising use of biologic anti-inflammatory therapies, increasing adoption in rare autoinflammatory disorders, growing focus on long-term disease control, expansion of home-based injection therapies, increased use in off-label inflammatory conditions.

Global Anakinra Market Segmentation

1) By Indication: Rheumatoid Arthritis, Cryopyrin-Associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome, Systemic Juvenile Idiopathic Arthritis, Adult-Onset Still's Disease, Neonatal-Onset Multisystem Inflammatory Disease, Other Indications 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Wholesale Pharmacies 3) By End-User: Hospitals, Clinics, Homecare Settings Subsegments: 1) By Rheumatoid Arthritis: Moderate-to-Severe Disease, Early-stage Disease 2) By Cryopyrin-Associated Periodic Syndromes: Muckle-Wells Syndrome, Neonatal-Onset Multisystem Inflammatory Disease 3) By Familial Cold Autoinflammatory Syndrome: Acute Episodes, Chronic Symptoms 4) By Systemic Juvenile Idiopathic Arthritis: Active Systemic Disease, Inactive Disease With Flares 5) By Adult-Onset Still's Disease: Active Disease, Remission Induction 6) By Neonatal-Onset Multisystem Inflammatory Disease: Acute Disease Episodes, Long-term Disease Management 7) By Other Indications: Gouty Arthritis, Spondyloarthritis

What Are The Drivers Of The Anakinra Market?

The rising incidence of autoimmune disorders is expected to propel the growth of the anakinra market going forward. Autoimmune disorders refer to problems that occur when the body's immune system incorrectly assaults and destroys its own healthy tissues and organs, viewing them as foreign invaders. The rising incidence of autoimmune disorders is due to genetic predisposition and environmental factors, such as infections, pollution, and dietary changes, all contributing to the growing occurrence of these disorders. Anakinra is used to treat autoimmune disorders by blocking interleukin-1 (IL-1) activity, reducing inflammation in conditions like rheumatoid arthritis, Still’s disease, and periodic fever syndromes. For instance, in February 2025, according to the Australian Broadcasting Corporation, an Australia-based national public broadcaster, inflammatory bowel disease currently impacts almost 180,000 Australians, with Crohn's Disease affecting 93,700 and Ulcerative Colitis affecting 80,430 individuals, and the total number is expected to rise to 200,000 in the next 10 years. Therefore, the rising incidence of autoimmune disorders is driving the growth of the anakinra industry. Rising healthcare expenditure is expected to propel the growth of the anakinra market going forward. Healthcare expenditure refers to the total amount of money spent on healthcare services and products, including hospital care, physician services, medications, medical devices, and public health initiatives. Healthcare expenditure is rising due to factors such as an aging population, medical advancements, chronic disease prevalence, higher drug prices, increased healthcare utilization, administrative costs, and inflation. Healthcare expenditure supports anakinra by funding the development, accessibility, and ongoing administration of this targeted biologic therapy, ensuring that it remains an effective treatment for inflammatory conditions like rheumatoid arthritis, while facilitating its integration into healthcare systems through insurance coverage and patient access programs. For instance, in August 2025, according to Peterson-KFF Health System Tracker, a US-based tracking system that provides clear, up-to-date information on trends, drivers and issues that impact the performance of the system, by 2033, total health care spending in the United States is projected to reach $5.6 trillion, with hospitals accounting for the largest share at $1.8 trillion, while overall expenditures are expected to rise further to $8.6 trillion, including $2.7 trillion in hospital spending, $1.7 trillion in physician and clinic services, and $776 billion in prescription drug spending. Therefore, rising healthcare expenditure is driving the growth of the anakinra industry.

Key Players In The Global Anakinra Market

Major companies operating in the anakinra market are Swedish Orphan Biovitrum AB, Boehringer Ingelheim, Amgen Inc.

What Are Latest Mergers And Acquisitions In The Anakinra Market?

In March 2025, ViroGates A/S, a Denmark-based medical technology company, partnered with Swedish Orphan Biovitrum AB. This partnership aims to support the development and commercialization of suPARnostic in combination with Kineret (anakinra) in the US and Europe. This partnership aims to expand suPARnostic usage on multiple diagnostic platforms while incorporating a royalty payment structure for Sobi based on sales in both markets. Swedish Orphan Biovitrum AB is a Sweden-based specialised international biopharmaceutical company transforming the lives of people with rare diseases.

Regional Insights

North America was the largest region in the anakinra market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Anakinra Market?

The Anakinra market consists of sales of diagnostic kits, supportive care products, combination therapies, and biosimilars. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Anakinra Market Report 2026?

The anakinra market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the anakinra industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.